Current Hypertension Reviews最新文献

{"title":"Interactions between Hypertension and Breastfeeding: What Do We Know?","authors":"Aline do Carmo França-Botelho, Eduardo Luzia França, Adenilda Cristina Honório-França","doi":"10.2174/0115734021377669250418104703","DOIUrl":"https://doi.org/10.2174/0115734021377669250418104703","url":null,"abstract":"<p><p>Substantial evidence indicates that breastfeeding reduces mortality and morbidity in in-fants. However, social changes in the 20th century resulted in a considerable decline in breastfeed-ing rates in many countries. Breast milk is crucial because of its nutritional, immunological, and emotional benefits and economic value. Approximately 10% of pregnancies are complicated by hypertensive syndromes, which are the most commonly diagnosed conditions during pregnancy. This review aims to explore how hypertension may interfere with the quality of human breast milk. While numerous studies have investigated the composition of breast milk and its numerous benefits for both infants and mothers, limited research examines the relationship between colostrum, breast milk, and hypertension. Given the diverse nutritional and immunological components of breast milk, many questions remain about this complex interaction.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Efficacy of Integrating Yoga and Ayurveda for Hypertension Treatment.","authors":"Acharya Balkrishna, Ankita Kukreti, Deepika Srivastava, Ashwani Kumar, Vedpriya Arya","doi":"10.2174/0115734021350052250406161932","DOIUrl":"https://doi.org/10.2174/0115734021350052250406161932","url":null,"abstract":"<p><p>Hypertension, a condition affecting 1.28 billion adults globally, poses significant health risks, including damage to the heart, kidneys, and brain. Factors such as unhealthy lifestyles, poor dietary habits, obesity, and diabetes contribute to its prevalence. While pharmaceutical interven-tions are effective in controlling blood pressure, their adverse effects have led to growing interest in alternative therapies such as Ayurveda and Yoga. This review explores the potential of these traditional practices, individually and in combination, for managing hypertension. A thorough lit-erature review was conducted using databases like PubMed and Google Scholar to analyze peer-reviewed studies up to 2024. Ayurvedic treatments, including therapies like Basti and Shirodhara and herbal formulations such as Raktadabashamak Ghana Vati and Sarpagandha Vati, have shown promise in reducing blood pressure. Similarly, Yoga practices, including OM chanting and Yoga Nidra, have demonstrated stress-reducing and blood pressure-lowering effects. Despite evidence supporting their efficacy, research on their integrated use remains limited. This review underscores the importance of combining Ayurveda and Yoga for holistic hypertension management. Further scientific studies are necessary to validate this integrative approach, which has the potential to offer a safer, non-pharmacological alternative for managing hypertension and improving overall well-being.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Effect of Intermittent Fasting with Mediterranean Diet on Glycemic, Lipid, and Anthropometric Indices in Type 2 Diabetes: A Review of Randomized Controlled Trials.","authors":"Shakila Dehghani, Parisa Karimi, Narges Naimi Tarei, Mohammad Masoumvand, Mohammad Amin Nazari Manesh, Elmira Ramezani, Vahid Reza Askari","doi":"10.2174/0115734021351456250326051146","DOIUrl":"https://doi.org/10.2174/0115734021351456250326051146","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes is a metabolic disorder that is becoming more prevalent over time. Research has shown that the Mediterranean diet (MD) and intermittent fasting (IF) can improve the metabolic parameters of patients with type 2 diabetes. However, there has yet to be a study comparing the effectiveness of these two diets in diabetic patients. This review aims to com-pare the impact of the Mediterranean diet and intermittent fasting on glycemic, lipid, and anthro-pometric indices in patients with type 2 diabetes.</p><p><strong>Methods: </strong>We selected clinical trial studies published between 2013 and 2023 that examined the impact of the MD and the IF diet on glycemic, lipid, and anthropometric indices in patients with type 2 diabetes, in the PubMed and Scopus databases on November 23, 2023, and were included in our study following the PRISMA guidelines.</p><p><strong>Results: </strong>A total of 22 clinical trials meeting the inclusion criteria were chosen. Out of these, 13 clinical trials focused on the impact of the Mediterranean diet, while the remaining trials examined the effects of the IF diet on type 2 diabetes. The age range of participants in all studies was above 18 years, with the number of individuals investigated ranging from 9 to 557. The duration of the interventions varied from 1 week to 8 years. The MD and IF have both have been shown to effec-tively improve glycemic control, lipid profiles, and anthropometric measurements in patients with type 2 diabetes. However, the MD tends to offer more consistent and sustainable long-term bene-fits. This can be attributed to its rich composition of antioxidants, healthy fats, and dietary fiber. IF has demonstrated potential benefits for improving blood sugar levels and lipid profiles over short periods. However, its effectiveness may be compromised by the risk of hypoglycemia and the inconsistent commitment of patients.</p><p><strong>Conclusion: </strong>These findings suggest that the MD is preferable for long-term, while IF may serve as a complementary short-term strategy. Further research in this area is necessary to provide a definitive opinion.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Risk Factors and Clinical Complications of Chronic Kidney Disease (CKD) on Renal Arterial Resistive Index (RRI)","authors":"Zobin Souri, Alireza Ramezanzadeh, Elham Ramezanzadeh, Ehsan Kazemnezhad Leyli, Fatemeh Jalali-Zefrei","doi":"10.2174/0115734021346088241228184539","DOIUrl":"10.2174/0115734021346088241228184539","url":null,"abstract":"<p><strong>Background: </strong>Chronic Kidney Disease (CKD) is a known risk factor for End-Stage Renal Disease (ESRD) and Cardiovascular Diseases (CVD). Renal Doppler Ultrasound (RDU) can detect early renal involvement in CKD using the Renal Resistive Index (RRI).</p><p><strong>Aims: </strong>This study aimed to investigate the effects of risk factors and clinical complications associated with CKD on RRI among patients with different stages of CKD.</p><p><strong>Methods: </strong>In this analytical cross-sectional study, 186 patients referred to Poursina Hospital for RDU were categorized into six groups (normal and five stages of CKD). We analyzed the impact of demographic factors and clinical complications on RRI across all groups.</p><p><strong>Results: </strong>Our findings indicated that CKD prevalence was particularly high among older patients and those with CVD, type 2 diabetes mellitus (DM), and hypertension (HTN). Elevated RRI in CKD patients was significantly associated with age, CKD stage, CVD, and HTN (p < 0.05). Furthermore, RRI was higher in CKD patients with elevated serum phosphorus (P) levels, higher low-density lipoproteins (LDL), and lower calcium (Ca) and hemoglobin (Hb) levels. Based on a multivariate regression model, CVD, lower Ca, high LDL, and proteinuria were identified as independent predictors of elevated RRI (p < 0.05).</p><p><strong>Conclusion: </strong>This study concludes that elevated RRI is associated with the severity of CKD and its clinical complications, suggesting that RRI can serve as a reliable indicator for assessing CKD patients, managing treatment, and preventing early death complications.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Hypertension and High-Density Lipoprotein Cholesterol: A Narrative Review","authors":"Rufei Liu, Wenli Cheng","doi":"10.2174/0115734021345634241115115253","DOIUrl":"10.2174/0115734021345634241115115253","url":null,"abstract":"<p><p>Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn.</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Efficacy of Using ACEIs and ARBs in Chronotherapeutic Treatment of Hypertension: Which Drug When?","authors":"Jasmine Yadav, Naim Khan, RIna Das, Dinesh Kumar Mehta","doi":"10.2174/0115734021332079241226115916","DOIUrl":"10.2174/0115734021332079241226115916","url":null,"abstract":"<p><p>Hypertension, a prevalent global health issue, poses significant risks for morbidity and mortality. The interplay between hypertension and comorbidities like diabetes and chronic kidney disease (CKD) underscores the urgency for effective management strategies. Chronotherapy, aligning medication administration with circadian rhythms, emerges as a promising approach to optimize treatment outcomes. The objective of this study is to assess the safety and efficacy of the use of ACEIs and ARBs in the chronotherapeutic treatment of hypertension. We aim to clarify the influence of circadian blood pressure patterns on the efficacy of medications and investigate the potential of chronotherapy in the management of hypertension by conducting a thorough examination of the existing literature. A literature search spanning from January 1980 to 2023 was conducted using PubMed, Scopus and Google Scholar databases. Search terms included ACE inhibitors, ARBs, chronotherapy, hypertension, and circadian rhythm of blood pressure. Studies investigating the effects of chronotherapy with ACEIs and ARBs in hypertensive patients were analyzed. Chronotherapy offers a personalized approach to hypertension management, leveraging the dynamic nature of circadian rhythms. By administering ACEIs or ARBs at night, the risk of morning blood pressure surges, associated with adverse cardiovascular events, can be mitigated. However, the optimal timing and combination of medications remain areas of ongoing research. Our review highlights the potential of chronotherapy with ACEIs and ARBs as a promising avenue for hypertension treatment. Further research is warranted to elucidate the mechanisms underlying circadian blood pressure regulation and optimize chronotherapeutic strategies. This comprehensive evaluation underscores the need for personalized treatment approaches tailored to individual circadian rhythms for improved hypertension management and reduced cardiovascular risk.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"15-30"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of New Symmetrical and Asymmetrical 1,4-dihydropyridine Derivatives as Potential Antihypertensive Agents: An <i>In silico</i> Evaluation.","authors":"Ruhani Raj, Charu Parjapati, Minakshi Garg, Anupreet Kaur","doi":"10.2174/0115734021328359241206073629","DOIUrl":"10.2174/0115734021328359241206073629","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a worldwide problem that affects people of all ethnicities and social groups. Its mortality rate has been steadily increasing. However, several pharmacological compounds have been used to manage hypertension and related issues. Calcium Channel Blockers (CCBs) based on Dihydropyridine (DHP) are used as first-line therapy. It is well established that simple adjustments to an existing medicine's fundamental structure can considerably improve its efficacy.</p><p><strong>Materials and methods: </strong>The purpose of this research study was to create potential antihypertensive drugs utilizing a 1,4-DHP scaffold and analyze their binding processes with different calcium channel proteins for comparative analysis, with PDB IDs 3LV3, 1T0J, and 6DAF. This study used molecular docking and ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling to predict the binding efficacy of newly produced potential drugs, such as CCBs.</p><p><strong>Results: </strong>The binding energy of the protein with the newly created compounds ranged between -2.6 and -7.26 kcal/mol (3LV3), -7.42 to -10.36 kcal/mol (1T0J), and -6.63 to -11.98 kcal/mol (6DAF).</p><p><strong>Discussion: </strong>The predicted ADMET profiling yielded significant results, indicating that among the virtually prepared ligands, apart from the standard drugs amlodipine and nifedipine, ligand numbers 60 and 13 showed a favorable ADMET profile.</p><p><strong>Conclusion: </strong>In this study, drug development efforts focused on modifying existing hypertension medications through <i>in silico</i> analysis. From hundreds of synthesized ligands, 19 showed optimal docking scores. ADMET profiling of these 19 ligands revealed ligands 60 and 13 to have favorable profiles. The Swiss ADME and ADMET lab 2.0 tools confirmed these findings, highlighting their potential for further development.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"45-61"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Guido Grassi","doi":"10.2174/0115734021411011250501112641","DOIUrl":"10.2174/0115734021411011250501112641","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"63"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dose-response of Blood Pressure Variability in Stroke and Coronary Heart Disease.","authors":"Woro Riyadina, Sulistyowati Tuminah, Lely Indrawati, Nikson Sitorus, Alfons M Letelay, Tri Wurisastuti, Alifa Syamantha Putri, Ika Suswanti, Yuda Turana","doi":"10.2174/0115734021346604250214071418","DOIUrl":"10.2174/0115734021346604250214071418","url":null,"abstract":"<p><p>Introduction/ Objective: Blood pressure variability (BPV) is a potential predictor of vascular events and triggers target organ damage. This study aimed to determine the BPV in stroke and coronary heart disease (CHD) in the Bogor Cohort Study in Indonesia.</p><p><strong>Methods: </strong>Over six years of monitoring, a prospective cohort study was conducted on 1649 respondents aged ≥ 31 years from the Bogor Non-communicable Diseases Risk Factors Cohort Study. The dependent variable was vascular events (stroke or CHD), which were new cases (incidents) that appeared during the 6-year monitoring period (2011 - 2017 and 2012-2018).</p><p><strong>Result: </strong>During the six years of monitoring, the incidence of vascular events was 12.4 percent. The dose-response of systolic and diastolic BPV in vascular events, stroke, and coronary heart disease showed an increased risk (quintiles Q2, Q3, and Q4) compared to quintile 1 (Q1). Systolic BPV of ≥12,10 mmHg and diastolic BPV of ≥ 7,31 mmHg had a risk of 2.3 and 1.7 (95% Confidence Intervals (CI)), respectively, for vascular events during the period of 6-year observation, after controlling for age, hypertension status, and lipid profile.</p><p><strong>Conclusion: </strong>BPV is an independent predictor of vascular events, stroke, and coronary heart disease. The public and clinicians must pay attention to controlling BPV as a risk factor for vascular events, stroke, and CHD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"94-101"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Accuracy of 24-Hour Ambulatory Blood Pressure Monitoring <i>Versus</i> Clinic Blood Pressure for Cardiovascular and All-Cause Mortality: A Systematic Review and Meta-Analysis.","authors":"Hamidreza Soleimani, Negin S H Mohammadi, Sara M Namin, Amir Nasrollahizadeh, Tara Azardar, Kimia Najafi, Mehmet Cilingiroglu, Mushabbar Syed, Mani K Askari, Rahul Gupta, Wilbert S Aronow, Kaveh Hosseini","doi":"10.2174/0115734021337639250203175636","DOIUrl":"10.2174/0115734021337639250203175636","url":null,"abstract":"<p><strong>Introduction: </strong>According to current clinical practice guidelines, Ambulatory Blood Pressure Measurement (ABPM) is recommended to confirm diagnoses of hypertension. It remains unclear as to which method is superior in predicting mortality outcomes.</p><p><strong>Methods: </strong>Prospective observational studies, comparing ABPM with Clinical Blood Pressure Measurements (CBPM), were included with outcomes of the study being all-cause and cardiovascular mortality.</p><p><strong>Results: </strong>Nine studies with a total of 23,140 participants were included. Each 10-mmHg increase in 24-hour mean systolic blood pressure (SBP) was linked to a higher risk of all-cause mortality (HR: 1.13, 95% CI: 1.09-1.18), while Clinic Blood Pressure Measurement (CBPM) was not a significant predictor (HR: 1.02, 95% CI: 0.90-1.13). Nighttime SBP increases of 10 mmHg were associated with a higher all-cause mortality risk than daytime SBP (HR: 1.16, 95% CI: 1.11-1.21 <i>versus</i> HR: 1.08, 95% CI: 1.05-1.12). For cardiovascular mortality, a 10 mmHg increase in SBP yielded an HR of 1.21 (95% CI: 1.16-1.27) for 24-hour ABPM compared to 1.08 (95% CI: 1.04- 1.11) for CBPM. Similarly, for a 5 mmHg increase in Diastolic Blood Pressure (DBP), the HR was 1.14 (95% CI: 1.07-1.20) for 24 hour ABPM <i>versus</i> 1.04 (95% CI: 1.01-1.07) for clinical DBP, highlighting 24-hour monitoring as a stronger predictor for cardiovascular mortality.</p><p><strong>Conclusion: </strong>The findings of this study support the superiority of ABPM measurements in predicting both all-cause and cardiovascular mortality.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"102-116"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}